JP2021527129A - カルシフィラキシスを予防または治療するための方法および組成物 - Google Patents

カルシフィラキシスを予防または治療するための方法および組成物 Download PDF

Info

Publication number
JP2021527129A
JP2021527129A JP2021518057A JP2021518057A JP2021527129A JP 2021527129 A JP2021527129 A JP 2021527129A JP 2021518057 A JP2021518057 A JP 2021518057A JP 2021518057 A JP2021518057 A JP 2021518057A JP 2021527129 A JP2021527129 A JP 2021527129A
Authority
JP
Japan
Prior art keywords
subject
mkh2
administration
administered
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527129A5 (OSRAM
Inventor
ジェイムズ・エイ・タムリン
ポール・エル・ダーク
ジョン・エム・ルディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizon Pharma Inc
Original Assignee
Epizon Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizon Pharma Inc filed Critical Epizon Pharma Inc
Publication of JP2021527129A publication Critical patent/JP2021527129A/ja
Publication of JP2021527129A5 publication Critical patent/JP2021527129A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021518057A 2018-06-08 2019-06-07 カルシフィラキシスを予防または治療するための方法および組成物 Pending JP2021527129A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682794P 2018-06-08 2018-06-08
US62/682,794 2018-06-08
PCT/US2019/036139 WO2019237054A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating calciphylaxis

Publications (2)

Publication Number Publication Date
JP2021527129A true JP2021527129A (ja) 2021-10-11
JP2021527129A5 JP2021527129A5 (OSRAM) 2022-06-10

Family

ID=68763971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518057A Pending JP2021527129A (ja) 2018-06-08 2019-06-07 カルシフィラキシスを予防または治療するための方法および組成物

Country Status (11)

Country Link
US (7) US10736858B2 (OSRAM)
EP (1) EP3801478A4 (OSRAM)
JP (1) JP2021527129A (OSRAM)
KR (1) KR20210018422A (OSRAM)
CN (1) CN112955131A (OSRAM)
AU (1) AU2019282421B2 (OSRAM)
CA (1) CA3102979A1 (OSRAM)
IL (1) IL279246B2 (OSRAM)
MX (2) MX2020013301A (OSRAM)
SG (1) SG11202012055PA (OSRAM)
WO (1) WO2019237054A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025510392A (ja) * 2022-03-25 2025-04-14 南京盛徳生物科技研究院有限公司 心血管石灰化を改善するビタミンｋ２を含有する薬物組成物及びその調製方法と応用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210018423A (ko) 2018-06-08 2021-02-17 에피존 파마 인코포레이티드 조직 석회화의 예방 또는 치료를 위한 방법 및 조성물
MX2020013301A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Metodos y composiciones para prevenir o tratar calcifilaxis.
WO2020055678A1 (en) 2018-09-12 2020-03-19 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
MX2021008076A (es) * 2019-01-04 2021-12-10 Nattopharma As Terapia de combinacion de aglutinantes de fosfato y vitamina k.
CN112691058A (zh) * 2020-12-31 2021-04-23 玉溪健坤生物药业有限公司 一种含还原型维生素k2的牙膏及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176778A1 (en) 2001-08-03 2005-08-11 Vitak Bv Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification
US20050123603A1 (en) 2003-09-26 2005-06-09 Natural Asa Natural menaquinone 7 compositions
SI1728507T1 (sl) 2005-06-03 2011-07-29 Nattopharma Asa Uporaba vitamina K za reverziranje kalcifikacije krvnih Ĺľil
WO2007095630A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California New ubiquinone analogs and methods of use
JP5827784B2 (ja) * 2006-07-14 2015-12-02 ナットファルマ エーエスエー ビタミンｋ２を含む医薬及び栄養補助製品
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
AU2011324792A1 (en) * 2010-11-01 2013-05-30 Viridis Biopharma Pvt. Ltd Dynamic balancing of autonomic nervous system through vitamin MK-7
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
ES2869202T3 (es) 2012-06-18 2021-10-25 Fresenius Kabi Deutschland Gmbh Sistema de cánula para vía para la punción de vías centrales de acceso subcutáneo
WO2014191466A1 (en) 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
US9464021B2 (en) 2013-11-01 2016-10-11 Dilip S. Mehta Method of preparation of stereospecific quinone derivatives
GEP20197040B (en) 2015-03-20 2019-11-11 Gnosis Spa Solid forms of menaquinols
CN206387961U (zh) 2016-12-30 2017-08-08 孙淑芬 头戴显示设备
IT201700085412A1 (it) 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
US10368858B1 (en) 2018-01-25 2019-08-06 Ring Orthopedics, Inc. Suture passer
US11407704B2 (en) 2018-04-06 2022-08-09 Siec Badawcza Lukasiewicz-Instytut Chemii Przemyslowej Imienia Profesora Ignacego Moscickiego Process of vitamin K2 derivatives preparation
MX2020013301A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Metodos y composiciones para prevenir o tratar calcifilaxis.
KR20210018423A (ko) 2018-06-08 2021-02-17 에피존 파마 인코포레이티드 조직 석회화의 예방 또는 치료를 위한 방법 및 조성물
WO2020055678A1 (en) 2018-09-12 2020-03-19 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BASAVAIAS RAVISHANKAR, ET AL.: "Safety assessment of menaquinone-7 fo r use in human nutrition", JOURNAL OF FOOD AND DRUG ANALYSIS, vol. 23, JPN6023015742, 2015, pages 99 - 108, ISSN: 0005201041 *
MABEL AOUN, ET AL.: "High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vita", BMC NEPHROLOGY, vol. 18, no. 191, JPN6023015747, 2017, pages 1 - 10, ISSN: 0005201039 *
SARAH L. BOOTH: "Roles for Vitamin K Beyond Coagulation", ANNUAL REVIEW OF NUTRITION, vol. 29, no. 1, JPN6023047024, 1 August 2009 (2009-08-01), pages 89 - 110, ISSN: 0005201042 *
TOMASZ STOMPOR: "Coronary artery calcification in chronic kidney disease: An update", WORLD JOURNAL OF CARDIOLOGY, vol. 6, no. 4, JPN6023015750, 2014, pages 115 - 129, ISSN: 0005201040 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025510392A (ja) * 2022-03-25 2025-04-14 南京盛徳生物科技研究院有限公司 心血管石灰化を改善するビタミンｋ２を含有する薬物組成物及びその調製方法と応用
JP7805601B2 (ja) 2022-03-25 2026-01-26 南京盛徳生物科技研究院有限公司 薬物組成物及びその調製方法と使用

Also Published As

Publication number Publication date
MX2024010211A (es) 2024-09-02
US20200306207A1 (en) 2020-10-01
IL279246B2 (en) 2023-08-01
US20200360301A1 (en) 2020-11-19
US20200306208A1 (en) 2020-10-01
US10925838B2 (en) 2021-02-23
CA3102979A1 (en) 2019-12-12
US20200306206A1 (en) 2020-10-01
US11065212B2 (en) 2021-07-20
US10987320B2 (en) 2021-04-27
WO2019237054A1 (en) 2019-12-12
AU2019282421B2 (en) 2025-01-09
US20210378987A1 (en) 2021-12-09
KR20210018422A (ko) 2021-02-17
US20240041794A1 (en) 2024-02-08
MX2020013301A (es) 2021-05-12
IL279246A (en) 2021-01-31
AU2019282421A1 (en) 2021-01-07
US20190374483A1 (en) 2019-12-12
US12433854B2 (en) 2025-10-07
US10736858B2 (en) 2020-08-11
EP3801478A4 (en) 2022-02-23
US10940123B2 (en) 2021-03-09
CN112955131A (zh) 2021-06-11
SG11202012055PA (en) 2021-01-28
EP3801478A1 (en) 2021-04-14
IL279246B1 (en) 2023-04-01
US11793773B2 (en) 2023-10-24

Similar Documents

Publication Publication Date Title
JP7847880B2 (ja) 組織石灰化を予防または治療するための方法および組成物
US12433854B2 (en) Methods and compositions for preventing or treating calciphylaxis
JP5827784B2 (ja) ビタミンｋ２を含む医薬及び栄養補助製品

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231121